rosazol 1 % emulsiovoide
teva b.v. - metronidazole - emulsiovoide - 1 % - metronidatsoli
med-angin imeskelytabletti
divapharma gmbh - 2,4-dichlorbenzylalcoholum,levomentholum,amylmetacresolum - imeskelytabletti - diklooribentsyylialkoholi
med-angin sokeriton imeskelytabletti
divapharma gmbh - amylmetacresolum,2,4-dichlorbenzylalcoholum,levomentholum - imeskelytabletti - diklooribentsyylialkoholi
pinex 24 mg/ml oraaliliuos
actavis group ptc ehf - paracetamolum - oraaliliuos - 24 mg/ml - parasetamoli
ozawade
bioprojet pharma - pitolisant - sleep apnea, obstructive - muut hermoston huumeet - ozawade is indicated to improve wakefulness and reduce excessive daytime sleepiness (eds) in adult patients with obstructive sleep apnoea (osa).
ditustin 6 mg/ml oraaliliuos
teva b.v. - levodropropizine - oraaliliuos - 6 mg/ml - levodropropitsiini
natriumklorid abboxia 500 mg tabletti, kalvopäällysteinen
abboxia ab - sodium chloride - tabletti, kalvopäällysteinen - 500 mg - natriumkloridi
clopidogrel dura
mylan dura gmbh - clopidogrel (as hydrochloride) - peripheral vascular diseases; stroke; myocardial infarction - antitromboottiset aineet - klopidogreeli on tarkoitettu aikuisille aterotromboottisten tapahtumien estämiseen:potilaalla on ollut sydäninfarkti (josta on muutama vuorokausi, mutta enintään 35 vuorokautta), iskeeminen aivohalvaus (josta on 7 vuorokautta, mutta alle 6 kuukautta) tai perifeerinen valtimosairaus.
clopidogrel qualimed
qualimed - clopidogrel (as hydrochloride) - peripheral vascular diseases; stroke; myocardial infarction - antitromboottiset aineet - klopidogreeli on tarkoitettu aikuisille aterotromboottisten tapahtumien estämiseen:potilaalla on ollut sydäninfarkti (josta on muutama vuorokausi, mutta enintään 35 vuorokautta), iskeeminen aivohalvaus (josta on 7 vuorokautta, mutta alle 6 kuukautta) tai perifeerinen valtimosairaus. lisätietoja, katso kohta 5.
imatinib actavis
actavis group ptc ehf - imatinibi - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. vaikutukset imatinibi on luuytimensiirron lopputulokseen ei ole selvitetty. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. kokemusta imatinib potilailla, joilla on mds/mpd, jotka liittyvät pdgfr-geenin uudelleenjärjestäytymisen yhteydessä järjestelyt on hyvin rajallinen. ei ole kontrolloituja tutkimuksia, jotka osoittaisivat kliinistä tehoa tai eloonjäämisetua näissä sairauksia.